Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Infusion Topotecan With Erlotinib in Recurrent Ovarian Cancer
NCT01003938Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Aug 2009
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in ovarian cancer, sponsored by NYU Langone Health. Started Aug 2009; status: terminated.
02
Drugs
erlotinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01003938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003938.